Toward standardization in bladder cancer clinical trials: Guidance from the SITC-IBCG expert panel
J Immunother Cancer
.
2024 Feb 2;12(2):e008508.
doi: 10.1136/jitc-2023-008508.
Authors
Amanda A Myers
1
,
Ashish M Kamat
2
,
Angela Kilbert
3
,
Matthew D Galsky
4
Affiliations
1
Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
2
Department of Urology under Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA akamat@mdanderson.org.
3
Society for Immunotherapy of Cancer, Milwaukee, Wisconsin, USA.
4
Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York, New York, USA.
PMID:
38309724
PMCID:
PMC10840062
DOI:
10.1136/jitc-2023-008508
No abstract available
Keywords:
Clinical Trials as Topic; Guidelines as Topic; Urinary Bladder Neoplasms.
MeSH terms
Clinical Trials as Topic
Humans
Reference Standards
Urinary Bladder Neoplasms* / drug therapy